Engineered vaccine trains immune system to target COVID-19
NCT ID NCT04276896
First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times
Summary
This trial tests a new vaccine called LV-SMENP, designed to teach the body's immune cells to recognize and attack the COVID-19 virus. The vaccine uses a harmless virus to deliver pieces of the coronavirus into dendritic cells, which then activate T cells to fight infection. The study includes about 100 people with confirmed COVID-19 to see if the vaccine is safe and can improve symptoms or prevent severe pneumonia.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- LV-SMENP-DC vaccine and antigen-specific CTLs
- What this could lead to
- If successful, this vaccine could help prevent severe COVID-19 pneumonia and reduce deaths from the infection.
- What could go wrong
- This is an early-phase trial with only 100 participants, so the vaccine may not prove effective or safe for wider use. Side effects from the vaccine or immune cells are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
100 people
The number who actually took part.
- Started
-
Jun 2026
- Finished
-
Jul 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 months to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Laboratory (RT-PCR) confirmed Covid-19 infection in throat swab and/or sputum and/or lower respiratory tract samples; * The interval between the onset of symptoms and randomized is within 7 days. The onset of symptoms is mainly based on fever. If there is no fever, cough or other related symptoms can be used; * White blood cells ≥ 3,500 / μl, lymphocytes ≥ 750 / μl; * Human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or tuberculosis (TB) test is negative; * Sign the Informed Consent Form on a voluntary basis; Exclusion Criteria: * Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), or HTLV (HTLV antibody positive). * Subject is albumin-intolerant. * Subject with life expectancy less than 4 weeks. * Subject participated in other investigational somatic cell therapies within past 30 days. * Subject with positive pregnancy test result. * Researchers consider unsuitable.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pathogen infection COVID-19 infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, 518000, China